IMV Inc. downgraded to Neutral from Buy at B. Riley FBR » 08:2904/0104/01/20
B. Riley FBR analyst…
B. Riley FBR analyst Mayank Mamtani downgraded IMV Inc. to Neutral from Buy with a price target of $3, down from $7. The analyst sees increased uncertainty to DPX-Survivac's registration pathway in a "highly competitive" late-stage recurrent/refractory ovarian cancer landscape. Further, IMV's recent announcement of pursuing a COVID-19 vaccine puts additional pressure on a "relatively weak" balance sheet, Mamtani tells investors in a research note.
IMV Inc. provides up date on DPX-COVID-19 vaccine » 07:3003/3003/30/20
IMV Inc. provided…
IMV Inc. provided updates on the development of DPX-COVID-19, a vaccine candidate against the novel coronavirus, and on the company's business and clinical operations amid the COVID-19 pandemic. "As the COVID-19 pandemic continues to spread, we have taken all necessary measures to prioritize the health and safety of our employees, patients, investigators and each of their families. In parallel, we remain committed to serving the unmet needs of patients, both through our efforts to potentially develop a prophylactic vaccine to curb this novel coronavirus and across our ongoing clinical studies with DPX-Survivac in advanced-stage cancer patients," said Frederic Ors, CEO of IMV. "We are committed to progressing the development of our DPX-COVID-19 vaccine candidate working expeditiously with our partners to advance human clinical studies as fast as possible."
|Over a week ago|
IMV Inc. downgraded to Market Perform from Outperform at Raymond James » 15:0203/1803/18/20
Raymond James analyst…
Raymond James analyst David Novak downgraded IMV Inc. to Market Perform from Outperform with a price target of $3.00, down from $4.50.
IMV Inc. plans to advance clinical development of COVID-19 vaccine candidate » 07:1603/1803/18/20
IMV Inc. announced that…
IMV Inc. announced that it is advancing the clinical development of a DPX-based vaccine candidate against COVID-19. Vaccines against infectious disease have been a core part of IMV's heritage across its DPX platform technology. The goal of this development program will be to establish the clinical safety and immunogenicity of a vaccine candidate based on the Company's DPX delivery technology and incorporating peptides targeting novel epitopes from the coronavirus strain. The Company believes that this peptide-based approach, combined with the portability of the DPX platform, offers the potential for accelerated development and rapid, large-scale production of a vaccine. The company intends to develop its vaccine candidate DPX-COVID-19 in collaboration with lead investigators for the phase 1 clinical study: Joanne Langley, M.D. and Scott Halperin, M.D., of the Canadian Center for Vaccinology, or CCfV, at Dalhousie University, the Izaak Walton Killam Health Center and the Nova Scotia Health Authority and the Canadian Immunization Research Network, or CIRN; along with Dr. Gary Kobinger, Ph.D., Director of the Research Centre on Infectious Diseases at the University Laval in Quebec City and Global Urgent and Advanced Research and Development in Canada. The investigators will assist with preclinical and clinical evaluation and with further development strategy in collaboration with the Canadian government and others.
|Over a month ago|
IMV Inc. selloff this weekend is overdone, says B. Riley FBR » 09:0902/2802/28/20
B. Riley FBR analyst…
B. Riley FBR analyst Mayank Mamtani lowered the firm's price target on IMV Inc. to $7 from $11 and reiterates a Buy rating on the shares. The analyst believes the 40% selloff this week in the shares is overdone ahead of two key catalysts in Q2: the Phase II SPiReL DLBCL full readout and Phase II DPX-Survivac/Keytruda combination basket trial interim analysis in solid tumors. The reduced price target reflects IMV's longer therapy duration needed in its pivotal program and higher market volatility particularly for risk-on assets.
IMV Inc.to hold a KOL webcast » 08:3502/2702/27/20
Key Opinion Leader…
Key Opinion Leader Symposium on Role of Survivin in Cancer Biology and Potential of DPX-Survivac will be held on February 27 at 8:30 am. Webcast Link
IMV's DeCidE1 results 'quite encouraging,' says H.C. Wainwright » 11:4602/2502/25/20
H.C. Wainwright analyst…
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $11.50 price target on IMV Inc. after the company announced breakthrough data from its DeCidE1 study that "delivers the goods." Pantginis said that DPX-Survivac appears to be breaking new ground as project, as it was among the first in vivo T cell therapies to show clinical activity in hard-to-treat solid tumors. The analyst said that the results are "quite encouraging" to her, and point to a potential accelerated path forward following planned talks with the FDA.
IMV Inc. downgraded to Equal Weight at Wells Fargo » 11:2702/2502/25/20
As previously reported,…
As previously reported, Wells Fargo analyst Jim Birchenough downgraded IMV Inc. (IMV) to Equal Weight from Overweight with a price target of $3.50, down from $6, as he reduces the likelihood of success of DPX-Survivac following review of top-line DeCidE1 data for DPX-Survivac in advanced ovarian cancer. The analyst believes that reported response rate of 22% is difficult to separate from background response rate seen historically with accompanying low-dose cyclophosphamide and believes a clear path to approval is unclear. Birchenough would await longer term follow up data and translational data from DeCidE1 that might identify response factors as well as basket study results with Merck's (MRK) Keytruda to better assess DPX-Survivac opportunity.
IMV Inc. downgraded to Equal Weight from Overweight at Wells Fargo » 11:2102/2502/25/20
Wells Fargo analyst Jim…
Wells Fargo analyst Jim Birchenough downgraded IMV Inc. to Equal Weight from Overweight with a price target of $3.50, down from $6.00.
IMV Inc. to host conference call » 07:2502/2502/25/20
Management holds a…
Management holds a conference call to discuss updated results Of Phase 2 DeCidE1 Study on February 25 at 8 am. Webcast Link